NewsWatch: FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, but not for the general public

A bunch of advisors to the Meals and Drug Administration on Friday reframed a proposed approval of BioNTech and Pfizer’s COVID-19 booster for the overall inhabitants, and it as a substitute beneficial authorization of a further dose of the vaccine to folks no less than 65 years outdated and people at excessive danger for extreme illness.

blank blank

blank

https://www.marketwatch.com/latest-news | NewsWatch: FDA panel recommends Pfizer’s COVID-19 booster for 65 and older, however not for most people

PaulLeBlanc

PaulLeBlanc is a Interreviewed U.S. News Reporter based in London. His focus is on U.S. politics and the environment. He has covered climate change extensively, as well as healthcare and crime. PaulLeBlanc joined Interreviewed in 2023 from the Daily Express and previously worked for Chemist and Druggist and the Jewish Chronicle. He is a graduate of Cambridge University. Languages: English. You can get in touch with me by emailing: paulleblanc@interreviewed.com.

Related Articles

Back to top button